DCTH

Delcath Systems, Inc. 10-K Summary (Fiscal Year Ended Dec 31, 2010)

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2010, for Delcath Systems, Inc., a development-stage specialty pharmaceutical and medical device company focused on oncology. The Company's primary asset is the Delcath chemosaturation system, a platform technology designed to deliver high doses of chemotherapy (specifically melphalan) directly to the liver while filtering the blood to limit systemic exposure. The system targets metastatic melanoma in the liver and other liver cancers. As of the reporting date, the Company had no commercial revenue and was focused on obtaining regulatory approval to market the system.

Key Financial Metrics

Note: The Company reported no revenue. The significant increase in net loss was driven by higher operating expenses and a non-cash derivative instrument expense of $16.0 million related to warrant valuations.

Material Changes vs. Prior Period

• Increased Burn Rate: Net loss increased by 111% to $46.7 million, primarily due to a $17.2 million increase in operating costs and a $7.4 million increase in derivative instrument expense.
• Operational Expansion: Employee headcount grew from 17 to 47, leading to higher compensation and general administrative expenses ($13.2 million in 2010 vs. $3.9 million in 2009).
• R&D Acceleration: Research and development costs rose 83% to $17.6 million to support regulatory filings and clinical trial completion.
• Capital Position: Cash reserves increased by $10.1 million to $45.6 million, bolstered by a public offering in August 2010 that raised approximately $33.5 million in net proceeds.

Guidance, Outlook, and Risks

Regulatory Status:

• United States: In December 2010, the Company submitted a New Drug Application (NDA) to the FDA. In February 2011 (subsequent to year-end), the FDA issued a "Refusal to File" letter. Management intends to resubmit the NDA by September 30, 2011.
• Europe: A CE Mark Technical File was submitted in December 2010. Approval was expected in mid-2011, which would allow marketing in the European Economic Area (EEA).

Outlook: Management believes capital resources are sufficient to fund operations through 2011. The Company anticipates continued losses until regulatory approval is obtained and commercialization begins. Future funding may be required via equity or debt offerings.

Key Risks:

• Regulatory Approval: Failure to obtain FDA or CE Mark approval would prevent commercialization and render the business model unviable.
• Liquidity: Continued losses may exhaust capital resources, necessitating additional financing that may not be available on acceptable terms.
• Derivative Liability: Significant non-cash expenses related to warrant valuations impact reported net loss.
• Reimbursement: Uncertainty regarding third-party payer reimbursement for the procedure post-approval.

Investor Verification Checklist

• FDA Resubmission Timeline: Verify the Company's ability to address the FDA's "Refusal to File" concerns and resubmit the NDA by the targeted September 2011 date.
• CE Mark Approval: Confirm the status of the European CE Mark application and the timeline for commercial launch in the EEA.
• Cash Runway: Assess whether the $45.6 million cash balance is sufficient to fund operations through 2011 and into 2012, given the high burn rate.
• Derivative Liability: Monitor the fair value of warrant liabilities, as fluctuations in stock price will continue to generate significant non-cash expenses.
• Commercialization Readiness: Evaluate the status of the manufacturing facility in Queensbury, NY, and the recruitment of a sales force for potential market entry.